PMD3 PARTIAL RESPONDERS IN SCHIZOPHRENIA  by Millier, A. et al.
association between drug and lab outcomes for the cohort matched on demo-
graphic and comorbid information only (p0.001). There was no significant asso-
ciation in the cohort matched on biomarkers plus comorbid and demographic
variables (p0.414). CONCLUSIONS: PSM using administrative claims alone left
considerable channeling bias in the sample, and erroneous conclusions were
drawn from subsequent GMM analysis. Inclusion of biomarkers in the PSM re-
moved this bias and yielded non-significant GMM results. Administrative claims
data without biomarkers may not be sufficient for conducting PSM.
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OBJECTIVES: This study evaluated the benefits of VNS Therapy on health resource
utilization (HRU), epilepsy-related comorbidities, and costs over time in drug-re-
sistant epilepsy patients in a clinical practice setting. METHODS: An open-cohort
pre-post analysis was conducted using Medicaid data from FL, NJ, IA, MO, and KS
(January 1997-June 2009). Patients had1 neurologist visit with epilepsy diagnosis
(ICD-9 345.xx, 780.3, or 780.39), 1 procedure for VNS Therapy implantation, 1
anti-epileptic drug (AED), 6 months of pre- and post-VNS Therapy continuous
enrollment. The 6-months precedingVNSTherapy implantationwas designated as
Pre-VNS Therapy period. Post-VNS Therapy periodwas designated from the date of
VNS Therapy implantation until removal of device, death, or Medicaid disenroll-
ment. Univariate and multivariate Poisson regressions (incidence rate ratios [IRR]
and 95% confidence intervals [CI]) compared HRU and epilepsy-related comorbidi-
ties and GLM models estimated cost differences between the pre- and post-VNS
Therapy periods. Costs were adjusted to $2009 using medical care component of
the consumer price index. RESULTS:Of the 1655 patients, mean age was 29.4 years
and 51.4% were males. Compared to Pre-VNS Therapy period the incidence of
hospitalizations and emergency room (ER) visits decreased over time during Post-
VNS Therapy period (Trend: 0.9238, p.0001 and Trend: 0.9526, p.0001, respec-
tively). Generalized tonic-clonic seizure events showed a decreasing trend during
Post-VNS Therapy period than Pre-VNS Therapy period (adjusted IRR: 1.23 [CI:
1.03-1.46] in Q1 to 0.17 [CI: 0.11-0.27] in Q12). During Post-VNS Therapy period,
average total health care costs decreased from $42,540 (Q1) to $14,316 (Q12). After
1.5 years, cost savings in Post-VNSTherapy period started to outweigh total costs of
VNS Therapy device and implantation procedures. CONCLUSIONS: To conclude,
VNS Therapy is associated with decreased HRU and common epilepsy-related co-
morbidities, such as hospitalizations, ER visits and generalized tonic-clonic seizure
events, resulting in net cost savings for public payers after about 1.5 years.
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OBJECTIVES:MildAlzheimer’sDisease (AD) is oftendifficult todifferentiate frommild
cognitive impairment (MCI) or non-ADdementias. Amultitude of diagnostic biomark-
ers and advanced imaging strategies have been developed to aid in the diagnosis and
management of AD. Examples of biomarkers include total tau, phosphorylated tau
(Ptau), and the 42 amino acid form of beta-amyloid (A1-42) and imaging strategies
include MRI, FDG-PET, SPECT and CT. We sought to systematically review and meta-
analyze the published evidence on key test characteristics of major diagnostic strate-
gies in AD. METHODS: A systematic review was undertaken to locate all studies of
biomarkers or diagnostic imaging for AD published in English from January 1990 to
March 2010. Meta-analysis was performed using a bivariate mixed-effects binary re-
gression model. We calculated sensitivity (SN), specificity (SP) and area under the
receiver operating curves (AUROC), with confidence and prediction contours in order
to formulate best estimates of SN and SP of commonly used diagnostic tests for AD.
RESULTS:Of 1,840unique studies identified, 119 presentedprimary data sufficient for
analysis. For each diagnostic method, SN and SP were calculated against non-de-
mented controls, non-AD dementias with andwithout MCI, if available. Compared to
non-demented controls, FDG-PET demonstrated the highest AUROC (0.96), with 90%
SN (95%CI 84% to 94%) and 89% SP (95% CI 81% to 94%). FDG-PET also wasmost accu-
rate in discriminating AD from demented controls (including MCI) with AUROC 0.91,
and 92% SN (95%CI 84% to 96%) and 78% SP (95% CI 69% to 85%). For discrimination of
AD from non-AD dementias (excluding MCI), CSF Ptau and SPECT produced identical
AUROC (0.86)with 79%and86%SNand80%and81%SP, respectively.CONCLUSIONS:
Diagnostic strategies for AD show wide variation in test characteristics and some
show promise for clinical practice.
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OBJECTIVES: Despite well conducted treatment, schizophrenic patients often re-
main symptomatic. Although multiple studies studied resistant patients, no data
are available on partial responders (PR). The purpose of this study is to compare
clinical, quality of life (QoL), cost of PR versus non symptomatic patients (full
respondersFR), and to assess the evolution of PR. METHODS: An analysis was
performed based on a sample of patients in France and UK followed prospectively
over 2 years. At baseline, resistant as well as acute exacerbated patients were
excluded. Symptomatic patients were defined according to 3 clinical criteria: CGI
score 4 and PANSS score 60 (with 3 items 4). Evolution was assessed over the
2 years period. The following information was collected using standardized vali-
dated instruments: psychotic symptoms, depression, side effects, compliance,
functioning, specific and generic QoL, resource utilisation. RESULTS: 93 (19%) pa-
tients were identified as PR and 284 (59%) as FR out of 484 patients. The population
of PR was well discriminated at baseline period when compared to FR. Clinical
symptoms including depression and side effects, compliance, functioning, QoL are
more severe in PR than in FR. Cost of management of PR appears significantly
higher than FR. Patients identified as PR remained PR over the 2 years period. The
change of prescription including switch, dosage increase or therapy augmentation
is similar between PR and FR. CONCLUSIONS: The PR is a stable population over-
time with higher clinical burden and increased management cost compared to FR.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of PR and related assessment of such intervention.
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OBJECTIVES: To assess the perception of iron deficiency and describe themanage-
ment of iron deficiency in clinical practices.METHODS: Physicians were randomly
selected from a professional directory. They reported in a questionnaire the esti-
mated frequency of iron deficiency and anemia among their patients, the biological
exams performed for iron deficiency diagnosis and the conditions of use of intra-
venous iron. The survey analysis was performed on 358 questionnaires (return
rate: 12%) from physicians of different areas of expertise (anesthesia, intensive
care, surgery, n67; gynecology, obstetrics, n122; oncology, hematology, radio-
therapy, n39; hepato-gastroenterology, internal medicine, geriatrics, rheumatol-
ogy, n130). RESULTS:Out of 86% (309/358) of the physicians reported cases of iron
deficiency. For 63% of them (223/358), the frequency of anemia among their pa-
tients wasmore than 10%. Survey responders were 25% (89/358) to report that they
systematically explored iron deficiency and 61% (217/358) only if anemia had been
previously diagnosed. Severe iron deficiency, is treated with oral iron in 75% (269/
358), 39% (141/358) with intravenous iron and 20% (70/358) with transfusion. For
70% of the physicians who prescribe intravenous iron (148/213) the limit threshold
of hemoglobin for prescription of intravenous iron of 8 g/dL (median). In contrast
with hemoglobin level, serum ferritin and transferrin saturation,were infrequently
performed (15% [31/213] and 5% [11/213], respectively). The use of erythropoiesis-
stimulating agents was reported by 44% (156/358) of physicians with systematic
iron supplementation for only 47% (74/156) of them. CONCLUSIONS: One of the
main results of this survey is the apparent equation between iron deficiency and
anemia in many physicians. Thus, most physicians report that intravenous iron is
used when hemoglobin is at a median value  8 g/dL, Therefore, iron deficiency is
considered only within a context of severe anemia for many physicians.
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OBJECTIVES: This pilot studywas to evaluate and compare drug eluting stent (DES)
and bare metal stent (BMS) in 1) clinical outcome; 2) humanistic outcome; and 3)
economic outcome, in patients undergoing percutaneous coronary intervention
(PCI). METHODS: All patients undergo PCI in Prince of Wales Hospital during Au-
gust 1 to October 31, 2009 were recruited. Clinical outcome was measured by the
occurrence of major adverse cardiac events (MACE), which is defined as cardiac
death, non-fatal MI and target lesion revascularization. An EQ-5D questionnaire
was used tomeasure the baseline quality of life before the stent placement, and six
months post PCI. Procedural cost including the instruments, medications and hos-
pitalization, as well as all cardiac related follow-up for the first six months was
recorded. Cost to reduce one MACE (ICER) and cost to gain one quality-adjusted
life-year (QALY) was calculated to assess the cost-effectiveness of DES. RESULTS:A
total of 50 patients (n22 and n28 for DES and BMS respectively) were enrolled
into our study. MACE in 6 month was 5% in DES (n1) versus 7% (n2) in BMS
respectively (p0.701). In DES group, the utility score showed significant improve-
ment in six months than baseline (0.92, IQR 0.80–1.00 vs. 0.69, IQR 0.22–0.77,
p0.001), while there were no significant improvement for BMS group (0.87, IQR
0.73–1.00 vs. 0.81, IQR 0.66–1.00, p0.337). ICER calculated was HKD$17,112 and
cost per QALY gained was HKD$142,600. six-month total medical cost was similar,
HKD$92,44058,566 for DES (median$74231) versus $95,22364,301 for BMS (me-
dian$76475) respectively, p0.875, the higher procedural cost of DES group was
balanced by lower follow-up and hospitalization cost, when compared with BMS
group.CONCLUSIONS:Thequality of life of patient underwent placementwithDES
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